Neuren Pharmaceuticals (NEU AU): Daybue US Sales and Geography Expansion to Drive Growth
Neuren Pharmaceuticals got confirmation from the FDA for the primary endpoints for its planned Phase 3 pivotal clinical trial of NNZ-2591 in Phelan...
488 Views
Neuren Pharmaceuticals (NEU AU): Substantial Buyback Plan Announced; Daybue Sales Accelerate in US
Neuren announces A$50M share buy-back program following the company's recent entitlement of one-off income from the sale of partner’s Priority...
282 Views
Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather
Neuren shares dip due to disappointing U.S. performance of Daybue. Muted US performance of Daybue in 1H24 seems to be short-lived and the drug is...
445 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
677 Views
APAC Healthcare Weekly (Mar 30)- Eisai, Kaken, Mochida, Shionogi, SK Bioscience, PharmaEssentia
Eisai outlined Leqembi sales target. Kaken inlicensed drug candidate. Mochida filed for Actembra biosimilar. Shionogi applied for label expansion...
411 Views